Non small cell lung cancer
Conditions
Interventions
Furmonertinib+ chemotherapy:Furmonertinib+ Pemetrexed + Carboplatin
Sponsors
Jiangsu Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients should voluntarily participate in the study, sign the informed consent form, have good compliance and cooperate with the follow-up; 2. Age 18-75 years old, with no restriction on gender; 3. Resectable stage II-IIIA NSCLC confirmed by pathological and imaging examinations; 4. EGFR-sensitive mutations (either exon 19 deletion or L858R in exon21); 5. ECOG score 0-1; 6. Treatment-na?ve patients who have not received any anti-tumor therapy previously; 7. No serious abnormalities of hematopoietic function, heart, lung, liver,kidney function and immune system.
Exclusion criteria
Exclusion criteria: 1. Received surgical treatment for lung tumors; 2. Received neoadjuvant chemotherapy or radiotherapy; 3. Confirmed with hepatocellular carcinoma (HCC) or any active liver disease uncontrolled by treatment; 4. Treated but uncontrolled diabetes mellitus, asthma, autoimmune diseases and other chronic diseases; 5. Received cellular therapy within the last 1 year; 6. Participated in other clinical trials (including research vaccines, drugs,medical devices, etc.) within one month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Pathological complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major pathological response rate;R0 resection rate;NAT treatment completion rate;Disease free survival;Overall survival;Adverse events/Serious adverse events; | — |
Countries
China
Contacts
Public ContactZhaohui Fan
Jiangsu Cancer Institute & Hospital
Outcome results
None listed